Skip to main content
. 2022 Nov 4;50(3):859–869. doi: 10.1007/s00259-022-06006-1

Table 3.

Survival of recurrent glioma patient groups according to tracer uptake

All recurrent glioma cases PRS (median; months) p-value TTF (median; months) p-value

All diagnoses (n = 88)

SUVmax ≤ 1.68 (n = 44)

SUVmax > 1.68 (n = 44)

27.9

41.6

12.6

 < 0.001

8.7

14.9

6.2

 < 0.001

All IDH-wildtype (n = 42)

SUVmax ≤ 1.89 (n = 21)

SUVmax > 1.89 (n = 21)

10.6

Not reached

8.2

 0.002

6.1

5.4

6.8

 0.142

All IDH-mutant (46)

SUVmax ≤ 1.60 (n = 23)

SUVmax > 1.60 (n = 23)

36.9

41.6

25.3

 0.031

18.4

32.2

8.7

 0.001

All astrocytoma, IDH-mutant (28)

SUVmax ≤ 1.72 (14)

SUVmax > 1.72 (14)

27.9

36.9

13.5

 0. 009

11.7

22.6

6.2

 0.007

Astrocytoma WHO 2021 grade 3, IDH mutant (17)

SUVmax ≤ 1.55 (9)

SUVmax > 1.55 (8)

36.9

36.9

13.1

 0.015

11.7

32.2

2.7

 0.025

All low-grade (2 or 3) astrocytoma, IDH-mutant (18)

SUVmax ≤ 1.33 (9)

SUVmax > 1.33 (9)

36.9

36.9

13.1

 0.003

14.5

32.2

6.2

 0.063

All oligodendroglioma, IDH-mutant and 1p/19q codeleted (18)

SUVmax ≤ 1.28 (9)

SUVmax > 1.28 (9)

Not reached

Not reached

Not reached

 0.464

Not reached

Not reached

18.4

 0.147

SUVmax maximum standardized uptake value, IDH isocitrate dehydrogenase, PRS post recurrence survival, TTF time to treatment failure